By Jack Hough
December 18, 2003
MOMENTUM FOR the reintroduction of silicone breast implants, banned
for the last 11 years, has Wall Street analysts ogling
profit-augmentation opportunities for the companies that make them.
The challenge, though, has been to forecast accurately how much market
share silicone could take from saline. A recent survey of the top 127
surgeons in the business yielded some surprising results. We'll tell
you all about it in a moment when we take a closer look at Santa
Barbara, Calif.-based Inamed (IMDC), a survivor of our recent Rising
Expectations screen.
~~~~~~~~~~
For more information on this ongoing debacle, please visit: